Four months after Theravance Biopharma shut down its R&D unit, laid off half its staff and signaled it was up for sale, the ...
Viridian Therapeutics has scored an FDA approval for Lumvoa to treat thyroid eye disease (TED), triggering competition with ...
In rejecting NASP, the FDA is delaying the launch of a gout drug that Sobi projected could reach up to 6 billion Swedish kroner ($620 million) in peak sales. (Photo by Sarah Silbiger/Getty Images) ...
The European Commission has kicked off formal proceedings in an antitrust investigation against Sanofi. The probe surrounds ...
As a sweltering heat wave hit Europe, a swath of pharma companies and healthcare marketing agencies from around the world ...
Bayer has scored a key victory in its defense against Roundup lawsuits as the U.S. Supreme Court has tossed a $1.25 million ...
In the past two weeks, CARsgen Therapeutics won the world's first regulatory approval for a solid tumor CAR-T Biologics' ...
He added that the company's plan to sell Foundayo through government channels will depend on the pricing implications of the ...
German generics maker Stada is back to business after being acquired by CapVest Partners last year, loading itself up with 16 ...
Driven by personal losses, major unmet needs and a desire to diversify from the crowded oncology market, Fosun Pharma is ...
The transaction is a big splash for Merck KGaA, representing the company’s largest deal since its buyout of Sigma-Aldrich for ...
Julianne Hough is the new face of Revance’s Botox rival Daxxify. | Julianne Hough is the new face of Revance’s Botox rival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results